A Phase 2 interventional study of aspirin and Exemestane in Breast Neoplasms, sponsored by Chinese Academy of Medical Sciences. Status unknown at 1 site in China. Open to female participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-03-13.
Sponsored by Chinese Academy of Medical Sciences · Phase 2, Interventional, and Prevention
This is a phase II study to assess efficacy/safety of Exemestane with or without Aspirin as the adjuvant treatment in postmenopausal breast cancer patients.
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's planned enrollment of 160 is above the median of 72 across 9,303 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Chinese Academy of Medical Sciences is the lead sponsor of 235 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: aspirin · Drug: Exemestane
Drug: Exemestane
Aspirin 50mg po daily
Exemestane 25mg po daily
Quality of Life
Time frame: 4 years
This study is status unknown, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese Academy of Medical Sciences